TITLE

ESC research cannot be ignored

AUTHOR(S)
Singh, Nandita
PUB. DATE
January 2012
SOURCE
BioSpectrum;Jan2012, Vol. 10 Issue 1, p100
SOURCE TYPE
Periodical
DOC. TYPE
Opinion
ABSTRACT
The author comments on the issues concerning embryonic stem cell (ESC) research in India. She highlights the decision of California-based Geron Corp. to exit in the market for ESC research to focus on other projects. She emphasizes the role of the government to impose policies to provide a clear direction for Indian researchers on the study of regenerative medicine.
ACCESSION #
72100752

 

Related Articles

  • Time to lift embryo research ban.  // Nature;11/12/1998, Vol. 396 Issue 6707, p97 

    Calls for a change in United States law regarding embryo research. Society's ability to regulate science; Advances in the culture of human embryonic stem cells; US ban on embryo research using federal funds; Lack of regulation for private sector; Geron, the company involved in embryo stem cell...

  • Stem cell revival. Coghlan, Andy // New Scientist;10/27/2012, Vol. 216 Issue 2888, p4 

    The article reports on attempts to resume a human embryonic stem cells (hESCs) clinical trial program cancelled in 2011 by the biotechnology company Geron, noting that former Geron officials and the biotechnology firm BioTime have placed a bid for the stem cell assets of the original program.

  • "CIRM Awards $25 Mln To Support Spinal-Cord Injury Trial, $37.7 Mln for Basic Stem-Cell Science".  // Biomedical Market Newsletter;5/9/2011, p143 

    The article reports that the Governing Board of the California Institute for Regenerative Medicine (CIRM), the State Stem Cell Agency, has approved a grant worth 25 million dollars to support the first U.S. Food & Drug Administration (FDA)-approved clinical trial based on cells derived from...

  • THE ESSENTIAL Guide to Stem Cells. Svoboda, Elizabeth // Popular Science;Jun2009, Vol. 274 Issue 6, p60 

    The article presents a collection of facts and information regarding stem cell research. It is noted how having the ban on U.S. funding for embryonic stem cell research lifted by U.S. President Barack Obama will improve the science. The first clinical trial of embryonic stem cells, being done by...

  • Is the End Coming for Embryonic Stem Cells? Cook, Michael // Australasian Science;Jan/Feb2012, Vol. 33 Issue 1, p48 

    The article looks at the implications of the cancellation of clinical trials for embryonic stem cell research in favour of adult stem cells. An overview of the debate over the ethical aspects of embryo research, therapeutic cloning and embryonic stem cells is provided. Biotechnology firm Geron...

  • Geron Seeks $100M in 'Long-Term' Funding. Wall, Tom // BioWorld Today;12/8/2010, Vol. 21 Issue 236, p1 

    This article reports on the public offering launched by Geron on December 2, 2010 that could raise as much as 100 million U.S. dollars. Proceeds from the offering will be used for clinical trials, clinical development of product candidates and general corporate purposes. A total of 17.4 million...

  • Temporary Stay Allows Stem Cell Funding: Appeals Court. Young, Donna // BioWorld Today;9/13/2010, Vol. 21 Issue 176, p1 

    The article reports on the decision of the U.S. Circuit Court of Appeals for the District of Columbia to allow the National Institutes of Health (NIH) to temporarily continue financing human embryonic stem cell (hESC) research. Such decision increased the shares of some hESC developers including...

  • Patent Office upholds Geron's embryonic stem cell patent.  // Medical Device Daily;2/29/2008, Vol. 12 Issue 41, p10 

    The article reports on the decision of the U.S. Patent and Trademark Office to uphold the validity of a key patent for human embryonic stem cells. The patent is assigned to the Wisconsin Alumni Foundation. To announce its decision, the agency issued an Action Closing Prosecution in the...

  • Geron & the Demise of Embryonic Stem-Cell Science. van Gend, David // Human Life Review;Winter2012, Vol. 38 Issue 1, p61 

    The article discusses aspects of embryonic stem-cell science research. The author talks about the decision of Geron Corp. to discontinue further developments of its embryonic stem cells (ESCs) programs. He looks into the discovery of induced pluripotent stem cells (iPSCs) derived from human skin...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics